27 results
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
and foreign countries;
changes in the structure of healthcare payment systems, especially in light of current reforms to the United States healthcare system … in Phase 2 development for the treatment of AD. The direct healthcare costs to care for patients with AD and other dementias in the U.S. is currently
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
in the structure of healthcare payment systems, especially in light of current reforms to the United States healthcare system;
the success or failure of our … of AD. The direct healthcare costs to care for patients with AD and other dementias in the U.S. is currently estimated to exceed $300 billion
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
12 Sep 23
Other Events
7:00am
to the Realities of US Healthcare System, Patients and Families
18 Gaps in development - stage candidates Breadth of Indication: AD spectrum including
8-K
EX-99.1
knl9gcapkbuxyry0n7
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
S-3
y3kqu 3wuw2r9
23 Dec 22
Shelf registration
4:16pm
8-K
EX-99.1
fgfpuflo12ta95qt75
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
424B4
msxl82c7de
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
mfr 44trk
20 Oct 22
Draft registration statement
12:00am
8-K
EX-99.1
6z7f0s95tm
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
8-K
EX-99.1
926ua0
16 Jun 22
Regulation FD Disclosure
7:08am
DEF 14A
ffuaucn7ae9gdgi7
25 Apr 22
Definitive proxy
5:28pm
10-K
2ht705ku6m a5
30 Mar 22
Annual report
7:40am
8-K
EX-99.1
9qdpz4rm
10 Jan 22
Regulation FD Disclosure
7:01am
10-Q
tcctom
17 Nov 21
Quarterly report
5:15pm